EUVIMEDEUVIMED entdecken
Crossref

Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis

Juan Li, Yi Shen, Xi Qiu, Xiaojin Lin, Jiahao He, Ni Ren, Jianuo Yang, Guanli Wang, Zhanjie Mo, Dakai Xiao, Chunli Liu iD

American Journal of Respiratory Cell and Molecular Biology · 2026

DOI: 10.1165/rcmb.2024-0352oc ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2026. Verfasst von Juan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Dep…. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, Hypertension, Pulmonary, Heart Ventricles, Pulmonary Artery. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Bureau-Key R&D Program, State Key Laboratory of Respiratory Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Lipid metabolism disorder is increasingly recognized as hallmarks of pulmonary hypertension (PH). Fatty acid-binding proteins (FABPs), particularly FABP4 and FABP5, which regulate lipid transport and metabolism of fatty acid, are thought to contribute to the development of PH. However, it remains unclear whether FABP4 and FABP5 serve as therapeutic targets for the treatment of PH. Measurements and Main.

Results

The levels of FABP4/5 were elevated in the plasma and lung tissues of idiopathic pulmonary arterial hypertension (IPAH) patients, as well as in the lung tissues of the PH rat model compared with control. The circulating levels of FABP4 of IPAH patients were correlated with mean pulmonary arterial pressure (mPAP). To determine the preventive or therapeutic effect of FABP4 and FABP5 inhibition, FABP4 and FABP5 inhibitors alone or combination were administered at early (days 2 following monocrotaline [MCT] injection) and late (day 12 following MCT injection) stage of PH rat model, respectively. Combined treatment with FABP4/5 inhibitors in the early stage of the MCT-PH rat model effectively reduced right ventricular systolic pressure (RVSP) and improved right ventricular (RV) function, accompanied by reductions in pulmonary vascular and RV fibrosis, as well as blood lipid levels, lipid peroxidation, and inflammation. Combined treatment with FABP4/5 inhibitors at the late stage of MCT-PH improved RV function, suppressed pulmonary vascular and RV fibrosis, and lowered blood lipid levels, but did not affect RVSP.

Conclusions

Combined inhibition of FABP4 and FABP5 can prevent the pathogenesis of PH, representing a potential therapeutic strategy for PH. p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acid-Binding ProteinsHypertension, PulmonaryHeart VentriclesPulmonary ArteryFamilial Primary Pulmonary HypertensionAnimalsMaleHumansRats, Sprague-DawleyRatsFibrosisFemaleDisease Models, AnimalMonocrotalineMiddle AgedLung

Stichwörter der Autor:innen

fatty acid-binding protein 4fatty acid-binding protein 5pulmonary hypertensionpulmonary vascular fibrosisright ventricular fibrosis

Substanzen

Fatty Acid-Binding ProteinsFABP4 protein, humanFABP5 protein, humanMonocrotaline

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute o…
  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Clinical Laboratory, Guangzhou Institute of Respiratory Hea…

ORCID-Profile: Chunli Liu

Förderung

  • Natural Science Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Bureau-Key R&D Program
  • State Key Laboratory of Respiratory Diseases
  • Academic Affairs Office of Guangzhou Medical University - 2022 Academic Innovation Ability Improvement Project

Zitieren

APA

Li, J., Shen, Y., Qiu, X., Lin, X., He, J., Ren, N., Yang, J., Wang, G., Mo, Z., Xiao, D., & Liu, C. (2026). Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2024-0352oc

Vancouver

Li J, Shen Y, Qiu X, Lin X, He J, Ren N, et al. Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis. American Journal of Respiratory Cell and Molecular Biology. 2026. doi:10.1165/rcmb.2024-0352oc

BibTeX
@article{Li2026,
  author = {Li, Juan and Shen, Yi and Qiu, Xi and Lin, Xiaojin and He, Jiahao and Ren, Ni and Yang, Jianuo and Wang, Guanli and Mo, Zhanjie and Xiao, Dakai and Liu, Chunli},
  title = {Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis},
  journal = {American Journal of Respiratory Cell and Molecular Biology},
  year = {2026},
  doi = {10.1165/rcmb.2024-0352oc}
}
Kostenlos starten →